Treatment of inflammatory conditions

Abstract

The present disclosure provides a method for treating an inflammatory condition, especially an age related inflammatory condition in a mammalian subject in need thereof, which comprises an effective amount of a virus like particle comprising a viral structural protein and a galectin-3 antigen, a composition or vaccine comprising for the purpose thereof.

What is claimed is: 
     
         1 . A method for treating an inflammatory condition in a subject in need thereof, which comprises an effective amount of a virus like particle comprising a viral structural protein and a galectin-3 antigen. 
     
     
         2 . The method according to  claim 1 , wherein the inflammatory condition is age related inflammatory condition. 
     
     
         3 . The method according to  claim 1 , wherein the inflammatory condition is an inflammation in a central nervous system (CNS). 
     
     
         4 . The method according to  claim 3 , wherein the inflammation in the CNS is a neurodegenerative disease. 
     
     
         5 . The method according to  claim 4 , wherein the neurogenerative disease is Parkinson's disease, amyotrophic lateral sclerosis (ALS, “Lou Gehrig's disease”), Huntington's disease, Alzheimer's disease, Creutzfeldt-Jakob disease or neuro-degenerative conditions in general. 
     
     
         6 . The method according to  claim 1 , wherein the viral structural protein is derived from alphavirus or flavivirus. 
     
     
         7 . The method according to  claim 1 , wherein the viral structural protein is derived from Chikungunya virus or Venezuelan equine encephalitis virus. 
     
     
         8 . The method according to  claim 7 , wherein the viral structural protein is derived from Chikungunya virus strain 37997 or strain OPY-1, or Venezuelan equine encephalitis virus strain TC-83. 
     
     
         9 . The method according to  claim 1 , wherein at least one galectin antigen is inserted into the envelope protein E3 of the viral structural protein. 
     
     
         10 . The method according to  claim 1 , wherein the galectin-3 antigen is selected from the peptides of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5. 
     
     
         11 . The VLP according  claim 1 , wherein the galectin-3 antigen is a peptide of SEQ ID NO: 12. 
     
     
         12 . The method according to  claim 7 , wherein the at least one galectin antigen is inserted between residues corresponding to 321 and 326 of SEQ ID NO: 1, residues 321 and 326 of SEQ ID NO: 2 or residues 330 and 335 of SEQ ID NO: 3. 
     
     
         13 . A pharmaceutical composition or vaccine composition for the treatment of an inflammatory condition in a mammalian subject, which comprises an effective amount of a virus like particle comprising a viral structural protein and a galectin antigen.